Loading the company…
Loading the company…
Families: Aortic endografts (EVAR/TEVAR), Coronary intervention (PCI), EP ablation.
All companies · Product and company coverage
In the last ten years FDA made 30 decisions for Endologix (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2020 (7). The latest was on 2026-06-03.
| Family | Decisions on record |
|---|---|
| Aortic endografts (EVAR/TEVAR) | 110 |
| Coronary intervention (PCI) | 3 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-06-03 | PMA | P120006-S045 | Alto Abdominal Stent Graft System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2024-09-27 | PMA | P120006-S044 | Alto Abdominal Stent Graft System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2024-09-27 | PMA | P040002-S075 | AFX2 Endovascular AAA System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2024-08-22 | PMA | P040002-S073 | AFX2 Endovascular AAA System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
In 2025, Endologix reported engagement with 1,812 surgeons and other clinicians in the states MedaRep covers, worth $1.3M in consulting, speaking, meals and travel for its device products, the most in New York ($164K to 163). Royalties are left out.
| 2024-08-22 | PMA | P040002-S072 | AFX2 Endovascular AAA System · Change Design/Components/Specifications/Material |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Endologix.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($164K, 163 engaged), California ($130K, 140 engaged), Texas ($108K, 255 engaged), Arizona ($101K, 55 engaged), Pennsylvania ($96K, 113 engaged).